ABBV AbbVie
Updated
S&P 500 CompaniesDividend Aristocrats
Healthcare · Pharmaceutical Preparations
AbbVie (ABBV) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $459.8 billion. Shares last traded at $260.21, near their 52-week high. Over the past year the stock is up 22.8%. ABBV trades at a price-to-earnings ratio of 72.87, above the Pharmaceutical Preparations median of 17.31. Net profit margin is 9.8%, above the peer median of -8.9%. Revenue grew 8.6% year over year. The shares yield 2.6% in dividends.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.
ABBV Dividend History
| Fiscal year end | Total dividends paid | Per share* | Payout ratio |
|---|---|---|---|
| 2025-12-31 | $11.66B | $6.57 | 276% |
| 2024-12-31 | $11.03B | $6.22 | 258% |
| 2023-12-31 | $10.54B | $5.94 | 217% |
| 2022-12-31 | $10.04B | $5.65 | 85% |
| 2021-12-31 | $9.26B | $5.21 | 80% |
| 2020-12-31 | $7.72B | $4.61 | 167% |
| 2019-12-31 | $6.37B | $4.29 | 81% |
| 2018-12-31 | $5.58B | $3.61 | 98% |
| 2017-12-31 | $4.11B | $2.56 | 77% |
| 2016-12-31 | $3.72B | $2.28 | 62% |
| 2015-12-31 | $3.29B | $2.01 | 64% |
| 2014-12-31 | $2.66B | $1.65 | 150% |
*Per share derived as total dividends paid ÷ weighted diluted shares (SEC EDGAR/XBRL annual cash-flow facts). Reported history — not a forecast of future dividends.
ABBV is a Dividend Aristocrat (25+ consecutive years of increases). Compare payers on the highest-dividend-yield screener.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $2.42 | 2026-08-03 |
| Q1 2026 | $0.39 | 2026-05-08 |
| FY 2025 | $2.36 | 2026-02-20 |
| Q3 2025 | $1.34 | 2025-11-04 |
| Q2 2026 | $1.24 | 2026-08-03 |
| Q1 2026 | $0.72 | 2026-05-08 |
Pharmaceutical Preparations peers
ABBV vs 14 industry peers (Pharmaceutical Preparations), by market cap. Updated
| LLY | Lilly (Eli) | $1.09T | 40.86 | 13.70 | 33.5% | -0.02% |
| JNJ | Johnson & Johnson | $670.6B | 31.88 | 6.85 | 21.5% | +1.04% |
| ONC | Beone Medicines Ltd. | $535.9B | 817.25 | 87.43 | 10.7% | +0.23% |
| ABBV | AbbVie | $459.8B | 72.87 | 7.14 | 9.8% | -0.57% |
| MRK | Merck | $375.8B | 118.44 | 5.65 | 4.8% | +0.44% |
| ABT | Abbott Laboratories | $189.5B | 30.20 | 4.20 | 13.9% | -1.50% |
| PFE | Pfizer | $164.2B | 37.91 | 2.58 | 6.8% | -0.76% |
| VRTX | Vertex Pharmaceuticals | $141.5B | 32.11 | 11.24 | 35.0% | +0.24% |
| BMY | Bristol Myers Squibb | $139.1B | 14.98 | 2.83 | 18.9% | +0.62% |
| REGN | Regeneron Pharmaceuticals | $87.2B | 20.15 | 5.61 | 27.9% | -1.02% |
| TEVA | Teva Pharmaceutical Industries Ltd | $42.6B | 60.41 | 2.46 | 4.1% | -2.32% |
| ALNY | Alnylam Pharmaceuticals | $35.4B | 43.77 | 9.52 | 21.8% | -1.10% |
| ZTS | Zoetis | $31.5B | 12.05 | 3.31 | 27.5% | +0.16% |
| RPRX | Royalty Pharma Plc | $28.2B | 34.56 | 11.11 | 32.1% | +1.24% |
🇨🇦 AbbVie also trades on Cboe Canada as a CAD-hedged Canadian Depositary Receipt (CDR) under ABBV. A CDR represents the same underlying ABBV shares in Canadian dollars with the currency exposure hedged; this page tracks the US-listed shares.
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.